Page last updated: 2024-12-10

psoralidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

psoralidin : A member of the class of coumestans that is coumestan substituted by hydroxy groups at positions 3 and 9 and a prenyl group at position 2 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281806
CHEMBL ID4064323
CHEBI ID8616
SCHEMBL ID3239072
MeSH IDM0268908

Synonyms (40)

Synonym
18642-23-4
psoralidin
3,9-dihydroxy-2-prenylcoumestan
LMPK12090007
3,9-dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one
unii-g16zuq069l
6h-benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-butenyl)-
3,9-dihydroxy-2-(3-methyl-2-butenyl)-6h-benzofuro(3,2-c)(1)benzopyran-6-one
g16zuq069l ,
FT-0688287
S5464
CS-3757
CHEBI:8616 ,
3,9-dihydroxy-2-(3-methylbut-2-en-1-yl)-6h-[1]benzofuro[3,2-c][1]benzopyran-6-one
SCHEMBL3239072
AC-34016
Q-100223
psoralidin [mi]
3-benzofurancarboxylic acid, 2-(2,4-dihydroxy-5-(3-methyl-2-butenyl)phenyl)-6-hydroxy-, .delta.-lactone
HY-N0232
DTXSID20171903 ,
AKOS026674261
dtxcid2094394
3,9-dihydroxy-2-(3-methylbut-2-en-1-yl)-6h-(1)benzofuro(3,2-c)(1)benzopyran-6-one
mfcd10566617
psoralidin (5)
bdbm246524
AS-18741
P2605
3,9-dihydroxy-2-(3-methylbut-2-en-1-yl)-6h-benzofuro[3,2-c]chromen-6-one
Q7256115
NCGC00388431-05
CHEMBL4064323
CCG-267867
6h-benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)-
3-benzofurancarboxylic acid, 2-(2,4-dihydroxy-5-(3-methyl-2-butenyl)phenyl)-6-hydroxy-, delta-lactone
3,9-dihydroxy-2-(3-methyl-2-butenyl)-6h-benzofuro[3,2-c][1]benzopyran-6-one
A921802
EN300-6730959
5,14-dihydroxy-4-(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one

Research Excerpts

Overview

Psoralidin (PSO) is a natural phenolic coumarin extracted from the seeds of Psoralea corylifolia L. It possessed anti-inflammatory and immunomodulatory effects. Psoralid in appears to be a novel agent that targets both BCSCs and BCCs.

ExcerptReferenceRelevance
"Psoralidin (PSO) is a natural phenolic coumarin extracted from the seeds of Psoralea corylifolia L. "( Psoralidin protects against cerebral hypoxia/reoxygenation injury: Role of GAS6/Axl signaling.
Ding, B; Lei, W; Li, X; Lu, C; Tian, Y; Wu, S; Wu, X; Wu, Z; Yang, W; Yang, Y; Zhang, S; Zhao, A, 2022
)
3.61
"Psoralidin is a metabolic product from the seed of psoraleacorylifolia, possessed anti-inflammatory and immunomodulatory effects. "( Psoralidin suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines.
Guo, H; Hao, D; He, B; Kong, L; Ma, R; Wang, B; Yang, X; Zhu, Z, 2017
)
3.34
"Psoralidin (PSO) is a natural phenolic coumarin that is extracted from the seeds of Psoralea corylifolia L. "( Mechanisms explaining the efficacy of psoralidin in cancer and osteoporosis, a review.
Jiang, S; Shang, J; Wu, X; Xin, Z; Xu, B; Yang, Y; Yu, Z, 2019
)
2.23
"Psoralidin appears to be a novel agent that targets both BCSCs and BCCs."( Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells.
Damodaran, C; Das, TP; Suman, S, 2013
)
1.11
"Psoralidin is a naturally occurring furanocoumarin isolated from Psoralea corylifolia possessing anticancer and chemopreventive properties."( The coumarin psoralidin enhances anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Bronikowska, J; Czuba, ZP; Jaworska, D; Krol, W; Szliszka, E, 2012
)
1.47

Effects

Psoralidine has a good active effect on postmenopausal antiosteoporosis. Psoralidin has been characterized as a full ER agonist, which activates the classical ER-signaling pathway in both ER-positive human breast and endometrial cell lines.

ExcerptReferenceRelevance
"Psoralidine has a good active effect on postmenopausal antiosteoporosis. "( [Study on effect of psoralidin on anti-experimental postmenopausal osteoporosis and its mechanism].
Li, JP; Lin, Q; Liu, SJ; Mo, XM; Wang, XJ; Yang, J; Zeng, Y, 2013
)
2.16
"Psoralidine has a good active effect on postmenopausal antiosteoporosis. "( [Study on effect of psoralidin on anti-experimental postmenopausal osteoporosis and its mechanism].
Li, JP; Lin, Q; Liu, SJ; Mo, XM; Wang, XJ; Yang, J; Zeng, Y, 2013
)
2.16
"Psoralidin has been characterized as a full ER agonist, which activates the classical ER-signaling pathway in both ER-positive human breast and endometrial cell lines as well as non-human cultured cells transiently expressing either ERα or ERβ."( Psoralidin, a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia.
Chang, M; Kil, YS; Kim, HD; Liu, X; Nam, JW; Pae, AN; Park, JH; Seo, EK; Song, YS; Viswanath, AN, 2014
)
2.57
"Psoralidin (PL) has recently been attracting more attention as a new anticancer agent candidate. "( Nanoencapsulation of psoralidin via chitosan and Eudragit S100 for enhancement of oral bioavailability.
Song, X; Xiang, C; Yin, J, 2016
)
2.2
"Psoralidin has shown a variety of biological and pharmacological activities such as anti-tumor anti-oxidant, anti-bacterial, anti-depressant and anti-inflammatory activities. "( Comparison of the in vitro metabolism of psoralidin among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes.
Mackie, B; Shan, L; Shi, X; Wang, J; Yang, S; Zhang, G, 2016
)
2.14
"Psoralidin has been reported to inhibit lipopolysaccharide (LPS)-induced nitric oxide (NO) production, but the mechanisms of the action remain unclear. "( Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways.
Chiou, WF; Don, MJ; Liao, JF; Wei, BL, 2011
)
3.25

Treatment

Psoralidin-treatment of CTPE cells inhibited the expression of Placenta Specific 8, a lysosomal protein essential for autophagosome and autolysosome fusion. The treatment also reversed the inhibitory effects of IL‑1β on B‑cell lymphoma 2 (Bcl‑2) expression.

ExcerptReferenceRelevance
"Psoralidin-treatment of CTPE cells inhibited the expression of Placenta Specific 8, a lysosomal protein essential for autophagosome and autolysosome fusion, which resulted in growth inhibition."( Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis.
Alatassi, H; Ankem, MK; Damodaran, C; Das, TP; Freedman, JH; Kolluru, V; Pal, D; Sears, S; Suman, S, 2017
)
1.18
"Psoralidin pretreatment also reversed the inhibitory effects of IL‑1β on B‑cell lymphoma 2 (Bcl‑2) expression, and decreased the IL‑1β‑induced expression of Bcl‑2‑associated X protein, matrix metalloproteinase (MMP)‑1 and MMP‑13."( Protective effects of psoralidin on IL‑1β‑induced chondrocyte apoptosis.
Rao, Z; Wang, J; Wang, S, 2018
)
1.52
"Treatment with psoralidin, however, inhibited both constitutive and EGF-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells."( Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer.
Damodaran, C; Kumar, R; Pahari, P; Rohr, J; Srinivasan, S, 2010
)
0.7

Pharmacokinetics

ExcerptReferenceRelevance
" The developed method was applied to evaluating the pharmacokinetic study of 13 bioactive compounds after oral administration of Psoraleae Fructus in rat of different genders."( Simultaneous characterization of multiple Psoraleae Fructus bioactive compounds in rat plasma by ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry for application in sex-related differences in pharmacokinetics.
Cheng, LY; Song, L; Wu, YL; Yang, L; Yu, YL; Zhang, Y; Zhou, K; Zhou, ZX, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" This article aimed to develop a nanoencapsulation formulation of PL using water-soluble chitosan and Eudragit S100 and to evaluate its potential for bioavailability enhancement."( Nanoencapsulation of psoralidin via chitosan and Eudragit S100 for enhancement of oral bioavailability.
Song, X; Xiang, C; Yin, J, 2016
)
0.75
" The ability of Psoralidin (Pso), a non-toxic, orally bioavailable compound to inhibit cadmium-induced autophagy to prevent prostate cancer was investigated."( Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis.
Alatassi, H; Ankem, MK; Damodaran, C; Das, TP; Freedman, JH; Kolluru, V; Pal, D; Sears, S; Suman, S, 2017
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
estrogen receptor agonistAn agonist at the estrogen receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
coumestansMembers of the class of benzofurochromene with a 6H-[1]benzofuro[3,2-c]chromene skeleton and its substituted derivatives. They are the 3,4-didehydroderivatives of pterocarpans.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
delta-lactoneA lactone having a six-membered lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusKi2.95000.00753.23929.1100AID1803390
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
leukotriene production involved in inflammatory responseArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
positive regulation of acute inflammatory responseArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
leukotriene biosynthetic processArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
lipoxygenase pathwayArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein homotrimerizationArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
cellular response to calcium ionArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
cellular oxidant detoxificationArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
arachidonate 5-lipoxygenase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
enzyme activator activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
enzyme bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
identical protein bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
protein-containing complex bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
arachidonic acid bindingArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
glutathione transferase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
glutathione peroxidase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
leukotriene-C4 synthase activityArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
nuclear envelopeArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulumArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulum membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear membraneArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
nuclear envelopeArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
endoplasmic reticulumArachidonate 5-lipoxygenase-activating proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1803390SARS-CoV PLpro Inhibition Assay from Article 10.3109/14756366.2012.753591: \\Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.\\2014Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 29, Issue:1
Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.
AID1446794Binding affinity to recombinant human 6His-tagged FLAP expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetric method2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
AID1717789Mixed inhibition of SARS-CoV N-terminal 6His-tagged TEV-fused papain-like protease expressed in Escherichia coli BL21(DE3) cells using Z-RLRGG-AMC as substrate by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1717788Inhibition of SARS-CoV N-terminal 6His-tagged TEV-fused papain-like protease expressed in Escherichia coli BL21(DE3) cells using Z-RLRGG-AMC as substrate by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.82)18.2507
2000's7 (12.73)29.6817
2010's32 (58.18)24.3611
2020's15 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.29 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index5.66 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]